California
 
CSE:MDM         FSE:2M0        OTCQB:MRPHF
Kelowna, British Columbia
info@marapharm.com
     Telephone:
778-583-4476

News Release

Feb 20, 2017 - Marapharm Ventures Inc. "Marapharm" announces an acquisition in California
 

Kelowna British Columbia. Marapharm has entered into an agreement to purchase a Medical Delivery Service with the specific and limited purpose to deliver, facilitate or coordinate cannabis transactions between qualified patients and caregivers. The delivery service is located in Rancho Mirage, located in the Coachella Valley, California. The Valley connects with the Greater Los Angeles area to the West, population 19,000,000. The population of the valley is 500,000 and in addition has 3.5 million annual conventioneers and tourists.

Marapharm purchased 80% of the shares of Moringa Cooperative, Inc. "Moringa" and 20% ownership remains with the founding group, who will continue to operate the business. Presently the DBA (doing business as) is MedicalDriveBy and a change to Marapharm Delivery or other names is being considered. Terms of the transaction are $300,000 US. Additional funds may be required for further delivery vehicles, expansion and working capital. Moringa is a cooperative corporation organized under the California Consumer Cooperative Corporation Law. The purpose of the corporation is to engage in any lawful activity and specific to cannabis transactions in California.

"Delivery services for cannabis are a big profit business in other locations in the United States and we're excited for our first one to be in California. Marapharm's business model is to be part of the entire marijuana experience in different States and countries, to grow it, sell it and now to deliver it. This is great diversity!" Linda Sampson, Marapharm, CEO.

Marapharm announces the granting of options to directors, consultants and or officers of 300,000 options exercisable for a period of 3 months at an exercise price of $1.40 and a further 800,000 options exercisable at $2.50 for 4 months.

ABOUT MARAPHARM VENTURES INC.
www.marapharm.com
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for it's land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com) and Sedar website (www.sedar.com) under the profile for Marapharm Ventures Inc.


FOR FURTHER INFORMATION:
www.marapharm.com or Linda Sampson, CEO, 778-583-4476, email info@marapharm.com

STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
 

 

 
CSE:MDM         FSE:2M0        OTCQB:MRPHF
Kelowna, British Columbia
info@marapharm.com
     Telephone:
778-583-4476

News Release

Nov 21, 2016 Marapharm Ventures Inc. announces a second agreement to acquire assets in California
 

Marapharm Ventures Inc. ("Marapharm") announces, that in addition to the transaction described in the news release dated November 14, 2016, it has entered into another agreement to purchase an industrial facility in southern California and three (3) medical marijuana licenses for manufacturing, cultivation, and retail uses. The land size is 0.32 acres and the existing building size is 2,756 square feet, with an 18-foot-ceiling clearance, for a purchase price of $950,000.00 USD, based on a purchase price of less than $350 USD per square foot. There is excess land for expansion on the corner parcel and the yard area is paved and suitable for greenhouse growing. The purchase is subject to, and contingent upon, completion of satisfactory due diligence, including background checks, and closing documentation for the issuances of the three (3) licenses to Marapharm within 60 days, with the closing to take place 60 days from the removal of contingencies. "We are really excited to have a second property as well as three more licenses in the California market. Marapharm is positioning to be an effective competitor and marketer in the most populous state in the nation. Smaller and well located facilities like this one are perfect for training staff and for product testing of new strains and products", says Linda Sampson, Marapharm CEO and director.
 
Marapharm also announces that one series of warrants has been fully exercised. The warrants were issued in an offering that closed on November 10, 2015, for an aggregate issuance of 661,250 units comprised of 661,250 common shares and 661,250 warrants exercisable into 661,250 common shares at an exercise price of $0.45 for one year. The maximum amount which could be received from the warrant exercises is $297,562.50, and this amount was received in full on November 10, 2016. In addition, warrants from an offering which closed on November 6, 2015, have also been fully exercised. The offering consisted of 1,247,000 units, each unit consisting of one (1) common share and one (1) common share purchase warrant, allowing the subscriber to purchase an additional common share at an exercise price of $0.75 within 1 year. As a result of the warrant exercise, Marapharm received $935,250.00 in full on November 6, 2016. The total amount received for the two warrant exercises is $1,232,812.50. In addition, other holders of warrants from other private placements are exercising their warrants in advance of the due dates and these amounts will be announced in due course.
 
ABOUT MARAPHARM VENTURES INC.
www.marapharm.com
Marapharm has 300,000 square feet of medical marijuana licenses and land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com) and Sedar website (www.sedar.com) under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION:
www.marapharm.com  or Linda Sampson, CEO, 778-583-4476 info@marapharm.com
 
STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
 
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
 

 

 

 

CSE: MDM       FSE: 2M0      OTCQB: MRPHF
Kelowna, British Columbia
info@marapharm.com     Telephone: 778-583-4476

 

News Release

Nov 16, 2016 Marapharm Ventures Inc. announces an agreement to acquire assets in California 

Marapharm Ventures Inc. ("Marapharm") announces that it has entered into an agreement to purchase an industrial facility in southern California and three (3) medical marijuana licenses for manufacturing, cultivation, and retail uses. The land size is 40,510 square feet and the existing building size is 6,875 square feet, with a 19-foot-ceiling clearance, for a purchase price of $3.2 million USD, based on $450 USD per square foot for the building and $65 USD per square foot for the land. The yard area is paved and suitable for greenhouse growing. The purchase is subject to, and contingent upon, completion of satisfactory due diligence, including background checks, and closing documentation for the issuances of the three (3) licenses to Marapharm within 120 days, with the closing to take place 120 days from the removal of contingencies.  

"We are really excited to have such a prize property as well as three licenses, and to be in the California market. The 'Yes' vote in California is significant for a number of reasons: (i) California, if it were a stand-alone state, would be the 6th largest economy in the world, with a population of 40 million people, and (ii) this decision means the entire West Coast of the United States has legalized recreational marijuana. Once Canada is legal, the West Coast all the way from Mexico to Alaska will be legal, so the opportunity is huge,” says Linda Sampson, Marapharm CEO.

 
ABOUT MARAPHARM VENTURES INC. 

Marapharm has 300,000 square feet of medical marijuana licenses, land, and facilities in WA and NV and, about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license, having since passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, known as ACMPR.


Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com) and Sedar website (www.sedar.com) under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION: 
www.marapharm.com  or Linda Sampson, CEO, 
778- 583 4476  info@marapharm.com
 
STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the 
CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
 
Forward Looking Statements 
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

 

 

MDM on CSE:
thecse.ca
| MRPHF on OTCQB:
otcmarkets.com
| 2M0 (zero) on FSE:
boerse-frankfurt.de